An open-label pharmacokinetic and pharmacodynamic study of anastrozole (Arimidex (TM)) used to treat pubertal boys with gynecomastia of recent onset

Trial Profile

An open-label pharmacokinetic and pharmacodynamic study of anastrozole (Arimidex (TM)) used to treat pubertal boys with gynecomastia of recent onset

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jan 2011

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Gynaecomastia
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 26 Jan 2011 Actual end date (1 Nov 2006) added as reported by ClinicalTrials.gov.
    • 26 Jan 2011 Actual initiation date changed from 5 May 2005 to 1 Jun 2005 as reported by ClinicalTrials.gov.
    • 01 Jun 2007 Status change from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top